Phapros Tbk PT
PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, X-Gra, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also pr… Read more
Phapros Tbk PT (PEHA) - Net Assets
Latest net assets as of June 2025: Rp395.57 Billion IDR
Based on the latest financial reports, Phapros Tbk PT (PEHA) has net assets worth Rp395.57 Billion IDR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp1.46 Trillion) and total liabilities (Rp1.06 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp395.57 Billion |
| % of Total Assets | 27.13% |
| Annual Growth Rate | 1.14% |
| 5-Year Change | -46.94% |
| 10-Year Change | -12.59% |
| Growth Volatility | 18.47 |
Phapros Tbk PT - Net Assets Trend (2011–2024)
This chart illustrates how Phapros Tbk PT's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Phapros Tbk PT (2011–2024)
The table below shows the annual net assets of Phapros Tbk PT from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Rp393.12 Billion | -48.97% |
| 2023-12-31 | Rp770.33 Billion | -0.19% |
| 2022-12-31 | Rp771.82 Billion | +4.16% |
| 2021-12-31 | Rp740.98 Billion | +0.01% |
| 2020-12-31 | Rp740.91 Billion | -9.82% |
| 2019-12-31 | Rp821.61 Billion | +4.03% |
| 2018-12-31 | Rp789.80 Billion | +12.60% |
| 2017-12-31 | Rp701.39 Billion | +12.75% |
| 2016-12-31 | Rp622.08 Billion | +38.33% |
| 2015-12-31 | Rp449.72 Billion | +10.16% |
| 2014-12-31 | Rp408.25 Billion | +4.31% |
| 2013-12-31 | Rp391.40 Billion | +4.20% |
| 2012-12-31 | Rp375.63 Billion | +10.75% |
| 2011-12-31 | Rp339.17 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Phapros Tbk PT's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 682.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rp84.00 Billion | 22.12% |
| Other Comprehensive Income | Rp655.40 Billion | 172.58% |
| Other Components | Rp17.14 Billion | 4.51% |
| Total Equity | Rp379.75 Billion | 100.00% |
Phapros Tbk PT Competitors by Market Cap
The table below lists competitors of Phapros Tbk PT ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Crown Lifters Limited
NSE:CROWN
|
$4.70 Million |
|
Pharmsville Co. Ltd
KQ:318010
|
$4.71 Million |
|
Great Divide Mining Ltd
AU:GDM
|
$4.71 Million |
|
Utility Business Alliance PCL
BK:UBA
|
$4.71 Million |
|
Timberwell Bhd
KLSE:7854
|
$4.70 Million |
|
Free Flow Inc
OTCQB:FFLO
|
$4.70 Million |
|
Blue Label Telecoms Ltd
JSE:BLU
|
$4.70 Million |
|
SAG Holdings Limited
NASDAQ:SAG
|
$4.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Phapros Tbk PT's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 749,534,237,000 to 379,753,679,000, a change of -369,780,558,000 (-49.3%).
- Net loss of 285,069,165,000 reduced equity.
- Dividend payments of 78,623,000 reduced retained earnings.
- Other comprehensive income increased equity by 12,960,476,000.
- Other factors decreased equity by 97,593,246,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp-285.07 Billion | -75.07% |
| Dividends Paid | Rp78.62 Million | -0.02% |
| Other Comprehensive Income | Rp12.96 Billion | +3.41% |
| Other Changes | Rp-97.59 Billion | -25.7% |
| Total Change | Rp- | -49.33% |
Book Value vs Market Value Analysis
This analysis compares Phapros Tbk PT's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.61x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | Rp403.77 | Rp278.00 | x |
| 2012-12-31 | Rp437.19 | Rp278.00 | x |
| 2013-12-31 | Rp455.92 | Rp278.00 | x |
| 2014-12-31 | Rp486.01 | Rp278.00 | x |
| 2015-12-31 | Rp535.38 | Rp278.00 | x |
| 2016-12-31 | Rp740.57 | Rp278.00 | x |
| 2017-12-31 | Rp834.99 | Rp278.00 | x |
| 2018-12-31 | Rp916.58 | Rp278.00 | x |
| 2019-12-31 | Rp952.99 | Rp278.00 | x |
| 2020-12-31 | Rp856.73 | Rp278.00 | x |
| 2021-12-31 | Rp856.53 | Rp278.00 | x |
| 2022-12-31 | Rp894.11 | Rp278.00 | x |
| 2023-12-31 | Rp892.30 | Rp278.00 | x |
| 2024-12-31 | Rp452.09 | Rp278.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Phapros Tbk PT utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -75.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -38.28%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 3.77x
- Recent ROE (-75.07%) is below the historical average (5.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 19.07% | 13.75% | 1.02x | 1.36x | Rp30.78 Billion |
| 2012 | 18.83% | 13.06% | 0.95x | 1.52x | Rp32.44 Billion |
| 2013 | 10.99% | 8.07% | 0.81x | 1.68x | Rp3.81 Billion |
| 2014 | 11.10% | 7.84% | 0.91x | 1.56x | Rp4.50 Billion |
| 2015 | 14.01% | 9.12% | 1.02x | 1.51x | Rp18.04 Billion |
| 2016 | 13.99% | 10.66% | 0.92x | 1.42x | Rp24.79 Billion |
| 2017 | 17.86% | 12.50% | 0.85x | 1.68x | Rp55.13 Billion |
| 2018 | 17.18% | 12.93% | 0.55x | 2.43x | Rp55.31 Billion |
| 2019 | 12.75% | 9.23% | 0.53x | 2.62x | Rp21.98 Billion |
| 2020 | 6.74% | 4.94% | 0.51x | 2.66x | Rp-23.48 Billion |
| 2021 | 1.54% | 1.05% | 0.57x | 2.56x | Rp-60.88 Billion |
| 2022 | 3.74% | 2.40% | 0.65x | 2.41x | Rp-47.04 Billion |
| 2023 | 0.80% | 0.59% | 0.57x | 2.36x | Rp-68.99 Billion |
| 2024 | -75.07% | -38.28% | 0.52x | 3.77x | Rp-323.04 Billion |
Industry Comparison
This section compares Phapros Tbk PT's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,262,640,964,565
- Average return on equity (ROE) among peers: 21.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Phapros Tbk PT (PEHA) | Rp395.57 Billion | 19.07% | 2.69x | $4.70 Million |
| Darya-Varia Laboratoria Tbk (DVLA) | $1.20 Trillion | 16.72% | 0.40x | $8.73 Million |
| Indofarma Tbk (INAF) | $292.57 Billion | 37.70% | 0.84x | $4.64 Million |
| Merck Tbk (MERK) | $416.74 Billion | 25.87% | 0.37x | $11.43 Million |
| Pyridam Farma Tbk (PYFA) | $118.93 Billion | 7.10% | 0.57x | $76.03 Million |
| Sido Muncul PT (SIDO) | $2.90 Trillion | 22.87% | 0.15x | $192.60 Million |
| Tempo Scan Pacific Tbk (TSPC) | $2.64 Trillion | 18.49% | 0.36x | $70.32 Million |